Abstract:The breast cancer susceptibility gene 1 (BRCA1) is a nuclear phosphoprotein involved in DNA double-strand break (DSB) repair and maintenance of genome stability. A single BRCA1 mutation leads to reduced levels of functional BRCA1 protein, such that DSB repair is compromised. It has been proposed that BRCA1 is a haploinsufficient tumor suppressor gene in some contexts, which when lost accelerates the mutation rate of other critical genes thus increasing neoplastic transformation. BRCA1 expression levels are modified through exogenous exposures, and modulating BRCA1 expression may alter tumour onset, progression, and treatment options. We hypothesize that compounds that increase BRCA1 expression and function may prevent the outgrowth of BRCA1-associated breast cancer. By contrast, compounds that reduce BRCA1 protein level could be used as combination therapries in conjunction with poly-ADP ribose polymerase (PARP) inhibitors. To achieve these goals, we generated BRCA1-reporter cell lines. Using CRISPR-assisted genome editing, we endogenously tagged the BRCA1 protein with HiBiT, an 11 amino acid luminescent tag. BRCA1-targeting was verified by sequencing and immunoblotting, and functional validation was performed with known modulators of BRCA1 expression. Our tests confirmed that HiBiT-tagging allows for sensitive measurement of BRCA1 protein levels, therefore permitting screenability. BRCA1-reporter cells were subsequently used to conduct a pilot screen (64 epigenetic-modifying drugs) and a high-content screen (6,000 compounds). We identified several compounds that modified BRCA1 protein expression (B-score >3*SD). The epigenetic drug library yielded five repressors and two activators, and the high-content screen identified 163 repressors and 12 activators. Validation studies have confirmed that the activator drug, aloxistatin can elevate BRCA1-HiBiT levels in a dose-dependent manner. Additionally, aloxistatin treatment increased BRCA1 expression and function in a panel of breast cells. We have also assessed 9 down-regulators of BRCA1 from the pilot and high-content screens. Each of these nine compounds reduced the expression of BRCA1 protein and synergized with the PARP inhibitor olaparib to inhibit cancer cell growth. Collectively, our ongoing studies suggest that BRCA1 activation may reduce cancer phenotypes and BRCA1 repression can sensitize breast cancer cells to PARP-inhibition and other chemotherapies. Overall, using our reporter cell lines we have identified a number of unique compounds that effectively modify BRCA1 expression and function that may have utility in the treatment and prevention of BRCA1-associated cancers. Citation Format: Erin Sellars, Margarita Savguira, Joanne Kotsopoulos, Leonardo Salmena. A screen to identify modifiers of BRCA1 protein level for cancer prevention and treatment [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr B042.

Functional Annotation of Variants of the BRCA2 Gene Via Locally Haploid Human Pluripotent Stem Cells.

Functional Analysis of Patient-Derived PALB2 Missense Variants of Uncertain Significance.

Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management

A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays

Accurate classification of BRCA1 variants with saturation genome editing

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editing

Abstract PR09: Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene

The functional impact of variants of uncertain significance in BRCA2

Functional analysis of BRCT missense mutations in BRCA1 -mutated Chinese Han familial breast cancer.

Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation

Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain

Abstract B013: A quest for deeper understanding of BRCA2 Variants of Uncertain Significance (VUS)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

Abstract A070: Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer

High-throughput functional evaluation of BRCA2 variants of unknown significance

Functional Assessment of Protein Variants in Structured Domains by Fluorescence Cross-Correlation Spectroscopy

Functional Assessment of Missense Variants of Uncertain Significance in the Cancer Susceptibility Gene PALB2

Abstract B042: A screen to identify modifiers of BRCA1 protein level for cancer prevention and treatment

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy

Functional interrogation of DNA damage response variants with base editing screens